P53 dysfunction precedes the activation of nuclear factor-κB during disease progression in mice expressing tax, a human t-cell leukemia virus type 1 oncoprotein

Carcinogenesis

Volumn 34, Issue 9, 2013, Pages 2129-2136

  Ohsugi, Takeo ^a   Ishida, Takaomi ^b   Shimasaki, Tatsuya ^c   Okada, Seiji ^a   Umezawa, Kazuo ^d  

^a KUMAMOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Center for Animal Resources and Development   (Japan)

^d AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 2; DEHYDROXYMETHYLEPOXYQUINOMICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MDMX; PROTEIN P50; PROTEIN P53; TAX PROTEIN; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DISEASE COURSE; DNA DAMAGE; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN T CELL LEUKEMIA VIRUS 1; LEUKEMIA CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; ONCOGENE C MYB; ONCOGENE C MYC; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPLEEN CELL; T CELL LEUKEMIA; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

ADULT; ANIMALS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE PRODUCTS, TAX; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; I-KAPPA B PROTEINS; JURKAT CELLS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MICE; NF-KAPPA B; ONCOGENE PROTEINS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84885409563     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt144     Document Type: Article

References (50)

1. Poiesz, B.J. et al. (1980) Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl Acad. Sci. USA, 77, 7415-7419.
2. Hinuma, Y. et al. (1981) Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc. Natl Acad. Sci. USA, 78, 6476-6480.
3. Grassmann, R. et al. (2005) Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene, 24, 5976-5985.
4. Matsuoka, M. et al. (2007) Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat. Rev. Cancer, 7, 270-280.
5. Verdonck, K. et al. (2007) Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect. Dis., 7, 266-281.
6. Watanabe, T. (1997) HTLV-1-associated diseases. Int. J. Hematol., 66, 257-278.
7. Vousden, K.H. et al. (2002) Live or let die: the cell's response to p53. Nat. Rev. Cancer, 2, 594-604.
8. Tabakin-Fix, Y. et al. (2006) Functional inactivation of p53 by human T-cell leukemia virus type 1 Tax protein: mechanisms and clinical implications. Carcinogenesis, 27, 673-681.
9. Sun, S.C. et al. (2005) Activation of NF-?B by HTLV-I and implications for cell transformation. Oncogene, 24, 5952-5964.
10. Rauch, D.A. et al. (2011) Targeting HTLV-1 activation of NF?B in mouse models and ATLL patients. Viruses, 3, 886-900.
11. Portis, T. et al. (2001) Analysis of p53 inactivation in a human T-cell leukemia virus type 1 Tax transgenic mouse model. J. Virol., 75, 2185-2193.
12. Hasegawa, H. et al. (2006) Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. Nat. Med., 12, 466-472.
13. Ohsugi, T. et al. (2007) The Tax protein of HTLV-1 promotes oncogenesis in not only immature T cells but also mature T cells. Nat. Med., 13, 527-528.
14. Ohsugi, T. et al. (2011) Low CD4/CD8 T-cell ratio associated with inflammatory arthropathy in human T-cell leukemia virus type I Tax transgenic mice. PLoS One, 6, e18518.
15. Ohsugi, T. et al. (2006) In vitro and in vivo antitumor activity of the NF-?B inhibitor DHMEQ in the human T-cell leukemia virus type I-infected cell line, HUT-102. Leuk. Res., 30, 90-97.
16. Ohsugi, T. et al. (2005) In vivo antitumor activity of the NF-?B inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia. Carcinogenesis, 26, 1382-1388.
17. Conradie, M.M. et al. (2007) Vanadate prevents glucocorticoid-induced apoptosis of osteoblasts in vitro and osteocytes in vivo. J. Endocrinol., 195, 229-240.
18. Kawai, M. et al. (2010) Elevation of cell proliferation via generation of reactive oxygen species by piperonyl butoxide contributes to its liver tumor-promoting effects in mice. Arch. Toxicol., 84, 155-164.
19. Yuan, J. et al. (2010) c-Myb promotes the survival of CD4+CD8+ doublepositive thymocytes through upregulation of Bcl-xL. J. Immunol., 184, 2793-2804.
20. Morimura, K. et al. (1999) LOH and mutational analysis of p53 alleles in mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Carcinogenesis, 20, 715-718.
21. Watanabe, M. et al. (2005) Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-?B, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood, 106, 2462-2471.
22. Feng, Z. et al. (2007) Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc. Natl Acad. Sci. USA, 104, 16633-16638.
23. Matsumoto, N. et al. (2000) Synthesis of NF-?B activation inhibitors derived from epoxyquinomicin C. Bioorg. Med. Chem. Lett., 10, 865-869.
24. Matsumoto, N. et al. (1997) Epoxyquinomicins A, B, C and D, new antibiotics from Amycolatopsis. II. Effect on type II collagen-induced arthritis in mice. J. Antibiot. (Tokyo), 50, 906-911.
25. Ohsugi, T. et al. (2007) Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines. Cancer Lett., 257, 206-215.
26. Takemoto, S. et al. (2000) p53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14(ARF)-MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells. Blood, 95, 3939-3944.
27. Levine, A.J. (1997) p53, the cellular gatekeeper for growth and division. Cell, 88, 323-331.
28. Nagai, H. et al. (1991) Genetic alteration of p53 in some patients with adult T-cell leukemia. Jpn. J. Cancer Res., 82, 1421-1427.
29. Yamato, K. et al. (1993) Aberrant expression of the p53 tumor suppressor gene in adult T-cell leukemia and HTLV-I-infected cells. Jpn. J. Cancer Res., 84, 4-8.
30. Kawase, T. et al. (2009) PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt. Cell, 136, 535-550.
31. Takahashi, A. (2002) Pre-irradiation at a low dose-rate blunted p53 response. J. Radiat. Res., 43, 1-9.
32. Hirao, A. et al. (2000) DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science, 287, 1824-1827.
33. Squatrito, M. et al. (2010) Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell, 18, 619-629.
34. Xiong, S. et al. (2010) Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res., 70, 7148-7154.
35. Sala, A. et al. (1996) Apoptotic response to oncogenic stimuli: cooperative and antagonistic interactions between c-myb and the growth suppressor p53. Cancer Res., 56, 1991-1996.
36. Jeong, S.J. et al. (2005) A novel NF-?B pathway involving IKKß and p65/RelA Ser-536 phosphorylation results in p53 Inhibition in the absence of NF-kappaB transcriptional activity. J. Biol. Chem., 280, 10326-10332.
37. Jeong, S.J. et al. (2004) HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity. Blood, 104, 1490-1497.
38. Jeong, S.J. et al. (2005) Activated AKT regulates NF-?B activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene, 24, 6719-6728.
39. Pise-Masison, C.A. et al. (2000) Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-?B pathway and is dependent on p53 phosphorylation. Mol. Cell. Biol., 20, 3377-3386.
40. Pise-Masison, C.A. et al. (1998) Inhibition of p53 transactivation function by the human T-cell lymphotropic virus type 1 Tax protein. J. Virol., 72, 1165-1170.
41. Pise-Masison, C.A. et al. (1998) Phosphorylation of p53: a novel pathway for p53 inactivation in human T-cell lymphotropic virus type 1-transformed cells. J. Virol., 72, 6348-6355.
42. Ariumi, Y. et al. (2000) HTLV-1 tax oncoprotein represses the p53-mediated trans-activation function through coactivator CBP sequestration. Oncogene, 19, 1491-1499.
43. Antoni, L. et al. (2007) CHK2 kinase: cancer susceptibility and cancer therapy-two sides of the same coin? Nat. Rev. Cancer, 7, 925-936.
44. Chandhasin, C. et al. (2008) Human T-cell leukemia virus type 1 tax attenuates the ATM-mediated cellular DNA damage response. J. Virol., 82, 6952-6961.
45. Park, H.U. et al. (2006) Human T-cell leukemia virus type 1 Tax attenuates ?-irradiation-induced apoptosis through physical interaction with Chk2. Oncogene, 25, 438-447.
46. Zane, L. et al. (2012) Wip1 and p53 contribute to HTLV-1 Tax-induced tumorigenesis. Retrovirology, 9, 114.
47. Okamoto, T. et al. (1989) Multi-step carcinogenesis model for adult T-cell leukemia. Jpn. J. Cancer Res., 80, 191-195.
48. Ohsugi, T. et al. (2008) Current topics in prevention of human T-cell leukemia virus type i infection: NF-KB inhibitors and APOBEC3. Int. Rev. Immunol., 27, 225-253.
49. Umezawa, K. (2006) Inhibition of tumor growth by NF-KB inhibitors. Cancer Sci., 97, 990-995.
50. Umezawa, K. (2011) Possible role of peritoneal NF-KB in peripheral inflammation and cancer: lessons from the inhibitor DHMEQ. Biomed. Pharmacother., 65, 252-259